Epimmune Licenses Gene Delivery Technologies

Epimmune Inc. has licensed Valentis, Inc.’s proprietary PINC gene delivery technology for Epimmune’s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Valentis has granted Epimmune a non-exclusive license to certain patented and non-patented technology for use in developing DNA vaccines against HIV and HCV Read more about Epimmune Licenses Gene Delivery Technologies[…]

Epimmune Receives Patent For Vaccine Technology

Epimmune Inc. announced that the U.S. Patent and Trademark Office has issued the Company a patent relating to the Company’s core vaccine technology. The patent is U.S. Patent Number 6,037,135 entitled “Methods of Making HLA Binding Peptides and Their Uses,” and it includes claims covering methods for using any genomic or protein sequence to discover Read more about Epimmune Receives Patent For Vaccine Technology[…]